NUS and A*STAR sign MoU with pharma companies
The Agency for Science, Technology and Research (A*STAR; Singapore’s lead public sector agency for economic oriented research) and the National University of Singapore (NUS) have signed a Memorandum of Understanding (MoU) with leading pharmaceutical companies GlaxoSmithKline (GSK), Pfizer, and Merck Sharp & Dohme (MSD) to establish the Pharma Innovation Programme Singapore (PIPS).
The focus areas for PIPS include continuous manufacturing, bio-catalysis, process analytical technology, advanced process control, and enhanced pharmaceutical operations. PIPS will bring together Singapore’s public sector research capabilities and the domain expertise of key players in the Pharma industry to improve and transform the manufacturing operations and technologies of the industry.
The MoU was signed at the inaugural Future Of Manufacturing (FoM) Summit. It was organised by A*STAR, with support from the Economic Development Board (EDB) Singapore and SPRING Singapore. The summit brings together senior top executives from Multinational Companies (MNCs), Large Local Enterprises (LLEs), senior government officials and leading technology providers to exchange ideas on adapting and capturing opportunities in the complex and fast evolving manufacturing landscape.